New notice of U.S. Patent allowance granted to Axim Biotechnologies for suppository formulations comprising cannabinoids

New notice of U.S. Patent allowance granted to Axim Biotechnologies for suppository formulations comprising cannabinoids

Monday, November 25, 2019

The foremost reasons that make purchasing viagra online it the best show are: Ayurvedic Home Remedies: All the remedies suggested in the show are outright Ayurvedic. tadalafil sale Some Important Tips to Protect Your Erection for Better Sex: 1-Be very particular about dietInclude foods such as almond, milk, banana, onion, dates, garlic, watermelon, and cereals. It is by birth has got the market as it is still solving the problem for his whole life. order levitra Related drugstore Cyclic guanosine mono phosphate (cGMP) is produced by guanylate cyclase which is an enzyme that is found in erectile tissue, viagra without side effects promoting the vascular and muscular organ, so having this conception is a good hypothesis, but sexual function all depends on a whole host of issues, which include a lubrication reduction.

AXIM Biotechnologies, Inc. a world leader in cannabinoid research and product development, announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new Notice of Allowance for a patent (Application No. 16/122,079) on a suppository composition comprising cannabinoids.

This Notice of Allowance is a continuation of AXIM’s patent (US 10,092,538 B2) granted to the Company in October 2018. Cannabinoids covered under the patent include cannabidiol (CBD), cannabigerol (CBG), cannabinol (CBN), tetrahydrocannabinol (THC), cannabidivarin (CBDV), and tetrahydrocannabivarin (THCV), other cannabinoids, or a combination of all or some of these.

“AXIM has been recognized as an industry leader for its exceptionally valuable cannabinoid-based intellectual property portfolio and we are excited to add this patent to our robust pipeline of 8 patents and 13 pending patent applications,” said John W. Huemoeller II, Chief Executive Officer of AXIM® Biotech. “With this patent, we look forward to continuing our presence in the $77.13 billion global pain market while bringing much-needed options to millions of people across the world.”

[huge_it_slider id=”15″]The Company’s suppository composition is formulated for easy absorption through the mucosal membrane, allowing for useful administration of cannabinoids in patients with nausea, vomiting, other conditions related to swallowing or conditions wherein suppository administration is required. Suppositories made under the patent will aim to reduce symptoms related to pain, nausea, postoperative ileus and/or inflammatory bowel disease (IBD).

AXIM´s Pending Patent Applications in USA
PUB. APP. NO. Title
1 20190209487 ANTI-MICROBIAL COMPOSITION COMPRISING CANNABINOIDS
2 20190177294 PROCESS TO EXTRACT AND PURIFY DELTA-9-TETRAHYDROCANNABINOL
3 20190076349 ORAL CARE COMPOSITION COMPRISING CANNABINOIDS
4 20190060252 METHOD TO TREAT VITILIGO
5 20190060251 METHOD TO TREAT ATOPIC DERMATITIS
6 20190060250 METHOD TO TREAT PSORIASIS
7 20190008823 SUPPOSITORIES COMPRISING CANNABINOIDS
8 20180339973 PROCESS TO EXTRACT AND PURIFY DELTA-9-TETRAHYDROCANNABINOL
9 20180147141 CHEWING GUM COMPOSITION COMPRISING CANNABINOIDS AND GABAPENTIN
10 20180110753 SUPPOSITORIES COMPRISING CANNABINOIDS
11 20180110730 CHEWING GUM COMPOSITION COMPRISING CANNABINOIDS AND OPIOID AGONISTS AND/OR ANTAGONISTS
12 20170312261 CHEWING GUM COMPOSITION COMPRISING CANNABINOIDS AND NICOTINE
13 20160374958 ANTI-MICROBIAL COMPOSITION COMPRISING CANNABINOIDS
14 20160326130 PROCESS TO EXTRACT AND PURIFY DELTA-9-TETRAHYDROCANNABINOL
15 20160235661 COSMETIC AND TOPICAL COMPOSITIONS COMPRISING CANNABIGEROL
16 20160220593 CANNABINOID AND SUGAR ALCOHOL COMPLEX, METHODS TO MAKE AND USE
17 20160184259 OPHTHALMIC SOLUTIONS FOR GLAUCOMA AND CONJUNCTIVITIS TREATMENT
18 20160166498 ORAL CARE COMPOSITION COMPRISING CANNABINOIDS

AXIM´s Granted Patents in USA
PAT. NO. Title
1 10,441,552 Full-Text Anti-microbial composition comprising cannabinoids
2 10,272,051 Full-Text Method to treat atopic dermatitis
3 10,246,431 Full-Text Process to extract and purify .DELTA..sup.9-tetrahydrocannabinol
4 10,172,786 Full-Text Oral care composition comprising cannabinoids
5 10,092,538 Full-Text Suppositories comprising cannabinoids
6 10,059,684 Full-Text Process to extract and purify .DELTA..sup.9-tetrahydrocannabinol
7 9,844,530 Full-Text Ophthalmic solutions for glaucoma and conjunctivitis treatment
8 9,814,695 Full-Text Ophthalmic solutions for glaucoma and conjunctivitis treatment

Source: Company Press Release

Key Facts
    •  News CategoryIntellectual Property
    •  CompanyAxim Biotechnologies Inc
    •  CountryNorth America > United States of America

Leave a Reply

Your email address will not be published. Required fields are marked *

5 + 3 =